Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT04928807
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
- NCT04928807 ↗
- Active, not recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Open-label, Controlled Phase III Clinical Trial of Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in the Treatment for Locally Advanced Rectal Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Rectal Cancer
- Interventions
- Short course radiotherapy sequential camrelizumab and chemotherapy
- Arms
- Short course radiotherapy sequential camrelizumab and chemotherapy · Experimental
- Long term concurrent chemoradiotherapy and sequential chemotherapy · Active comparator
- Enrollment
- 231
- Primary outcomes
- pathological complete response (pCR) rate
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology with Jiangsu HengRui Medicine Co., Ltd.
- Start
- Jul 20, 2021
- Primary completion
- Mar 1, 2023
- Results posted
- No
- Registry record
- NCT04928807 · updated Feb 27, 2026
Publications
linked from the registry- You Q, Jin M, Zhou B, Huang C, Lin Z, Hu J, Xue J, Chen X, Xiao Y, Li R, Zong Y, Wu M, Zhang T, Liu H. Gut microbiome components predict response to neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): a prospective study. Front Pharmacol. 2026 May 29;17:1829108. doi: 10.3389/fphar.2026.1829108. eCollection 2026. PubMed 42292847
- Zhang F, Yu D, Yang J, Zhai M, Li L, Zhao L, Wang J, Zhang T, Lin Z. Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short-course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer. Oncol Lett. 2023 Jun 7;26(1):319. doi: 10.3892/ol.2023.13905. eCollection 2023 Jul. PubMed 37332340